SEC EDGARSEP 291 min read$TEM

Schoenherr Thomas Edward sold $874K of TEM

Schoenherr Thomas Edward (CEO, Diagnostics) sold 10,281 shares of Tempus AI, Inc. (TEM) at $85.00 ($0.87M total) on 2026-09-25 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Schoenherr Thomas Edward

Published Sep 29, 2026, 8:15 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 29, 2026, 8:15 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$TEM

Bearish

medium confidence

Mentioned

$TEM

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$TEMBearishLow

Why it matters

Provides fresh data on insider holdings and recent disposal.

Market read

Insider sales are monitored by traders for potential signals; this modest sale may prompt short‑term caution.

What to watch

Potential tax planning or portfolio rebalancing could be driving the transaction.

Relevance 4/10Novelty 4/10Timing: post‑market filing

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TEMBearishMedium confidence

Context

CEO Thomas Edward Schoenherr sold 10,281 shares for $873,885 via a 10b5‑1 plan.

Expected impact

likely pressure as the market prices in the CEO's share disposal

Evidence & confidence

A $874K sale by the CEO, even under a pre‑arranged plan, can prompt traders to anticipate modest downside.

Market effects

Sector

Minimal impact on the broader diagnostics/AI sector.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale may be routine under a 10b5‑1 plan and not indicate any negative outlook.

Key entities

Company
Tempus AI, Inc.
AI‑driven diagnostics firm.
Person
Thomas Edward Schoenherr
CEO of Tempus AI.

Read at source ← All news

OCT 7

$TEMMed

Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure - Tempus AI (NASDAQ:TEM)

Tempus Inc. (TEM) expanded its collaboration with Moderna (MRNA) and Merck (MRK) to support the development of a cancer vaccine. Tempus will manage sample collection and provide NGS services. The company also partnered with Bristol Myers Squibb (BMY) to improve clinical trial design. Additionally, Tempus acquired Personalis (PSNL) for $1.5 billion to enhance cancer monitoring. TEM shares were down 1.94% to $70.58 at the time of publication.

benzinga.com3 min

OCT 6

$TEMMed

Tempus AI Stock After FDA Clearance for AI Heart Valve Detection

Tempus AI received FDA clearance for its AI tool, ECG-MR, which detects potential heart valve issues in at-risk patients. This expands the company's AI software offerings into cardiovascular diagnostics. Analysts project revenues of $2.6B and earnings of $18.7M by 2029, assuming 22% yearly revenue growth. The company aims to integrate its data and software tools across various medical fields, including oncology, genetics, and now cardiology.

simplywall.st3 min

OCT 2

$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

rttnews.com3 min

SEP 30

$AMDMed

Cathie Wood Sold $110 Million of AMD and Bought Nvidia Instead

ARK Invest sold $110.5M in AMD shares and bought $81.6M in Nvidia, along with other tech stocks. AMD is up 183.7% YTD, while Nvidia gained 22.11%. ARK's moves may reflect rebalancing, with no public explanation provided. AMD's market cap briefly hit $1T, and Nvidia announced a $150B buyback.

247wallst.com2 min

SEP 28

$TEMMedAI 8/10

Tempus Secures FDA Clearance For ECG-AI Software Designed To Detect Mitral Regurgitation

Tempus AI (TEM) received FDA clearance for Tempus ECG-MR, an AI software detecting moderate or severe mitral regurgitation in 12-lead ECGs. The tool aids in identifying high-risk patients aged 65+ with cardiovascular risk factors. TEM stock is up 1.45% at $86.25.

rttnews.com2 min

SEP 26

$ABEOMed

Abeona, NexGen, Nano Nuclear, SanDisk, Tempus Trending

Analysts initiated coverage on five stocks: Abeona (ABEO) with a $17 target, NexGen (NXE) at $14, Nano Nuclear (NNE) at $33, SanDisk (SNDK) at $2,400, and Tempus (TEM) at $75. Abeona's ZEVASKYN gene therapy, NexGen's uranium project, Nano Nuclear's KRONOS reactor, SanDisk's AI infrastructure, and Tempus's diagnostics business are key focuses.

tipranks.com3 min